A Comprehensive Review of the Complement System: Molecular Mechanisms, Regulatory Networks, and Therapeutic Applications

Hussien A. Abouelhag⁴

Department of Microbiology and Immunology, National Research Centre, 33 Bohouth St., Dokki, Cairo, Egypt.

Corresponding author:Prof. Abouelhag H. A. E-mail:drabouelhag5@gmail.com

Received: 29-08-2025 Accepted: 16-09-2025 Published online: 24-09-2025

DOI: https://doi.org/10.33687/ricosbiol.03.09.77

Abstract

The complement system represents a sophisticated immune surveillance network that bridges innate and adaptive immunity through a cascade of proteolytic reactions. Comprising over 50 proteins, this system provides first-line defense against pathogens, clears immune complexes, and maintains tissue homeostasis. However, dysregulated complement activation contributes significantly to the pathogenesis of autoimmune disorders, thrombotic microangiopathies, and inflammatory diseases. This review offers a comprehensive examination of the complement system's molecular architecture, focusing on the intricate mechanisms of its three activation pathways and their convergence on common effector functions. We detail the critical regulatory networks that maintain complement homeostasis and prevent host tissue damage. The review systematically analyzes the pathological consequences of complement dysregulation across various disease states and discusses the revolutionary advances in complement-targeted therapeutics. Finally, we explore emerging research directions and the future landscape of complement-based diagnostics and treatments, providing insights into the evolving understanding of this complex biological system.

Keywords: Complement System, Innate Immunity, Classical Pathway, Alternative Pathway, Lectin Pathway, Membrane Attack Complex, Complement Regulators, C3 Convertase, Therapeutic Inhibition, Autoimmune Diseases.

1. Introduction

The complement system constitutes a fundamental component of innate immunity, accounting for approximately 15% of the globulin fraction in human plasma and comprising more than 50 distinct proteins and receptors (Ricklin et al., 2016). Originally identified in the 1890s as a heat-labile serum component that "complemented" antibody-mediated bacterial killing, contemporary research has revealed complement's multifaceted roles in immune surveillance, tissue homeostasis, and developmental biology (Merle et al., 2015). The system operates through three distinct but interconnected activation pathways—classical, lectin, and alternative—that converge to generate powerful effector molecules including opsonins, anaphylatoxins, and the membrane attack complex (MAC). While indispensable for host defense, inadequate regulation of complement activation underlies numerous pathological conditions, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and age-related macular degeneration (AMD) (Noris and Remuzzi, 2013). This review provides a comprehensive analysis of the complement system's molecular mechanisms, regulatory networks, pathological implications, and therapeutic targeting.

2. Molecular Architecture of Complement Activation Pathways

The complement system employs three distinct initiation mechanisms that converge at the formation of C3 convertase enzymes, enabling rapid, amplified responses to diverse immunological challenges through a carefully orchestrated proteolytic cascade.

2.1. Classical Pathway: Antibody-Mediated Activation

The classical pathway represents the antibody-dependent arm of complement activation, initiated when the C1q component of the C1 complex binds to the Fc region of antigen-bound IgM or aggregated IgG (Bohlson et al., 2019). This interaction induces conformational changes in C1q, triggering autoactivation of associated serine proteases C1r and C1s. Activated C1s subsequently cleaves C4 into the anaphylatoxin C4a and the opsonin C4b, with the latter covalently attaching to microbial surfaces through its exposed thioester domain. Surface-bound C4b then serves as a platform for C2 binding, which is cleaved by C1s to generate the classical pathway C3 convertase (C4b2a). Beyond immune complexes, the classical pathway recognizes apoptotic cells, amyloid deposits, and certain pathogens through pattern recognition mechanisms independent of antibodies, highlighting its versatility in danger sensing (Bohlson et al., 2019).

2.2. Lectin Pathway: Pattern Recognition Initiation

The lectin pathway initiates through pattern recognition molecules including mannose-binding lectin (MBL), ficolins, and collectins, which bind specific carbohydrate patterns on microbial surfaces (Garred et al., 2016). These circulators complex with MBL-associated serine proteases (MASPs), with MASP-2 serving as the primary enzymatic component that cleaves C4 and C2 to form the C3 convertase C4b2a, identical to that generated by the classical pathway. The lectin pathway provides immediate defense against pathogens before adaptive immune responses develop, serving as a critical first line of defense against bacterial, viral, and fungal infections. Recent structural studies have revealed intricate mechanisms of pattern recognition and protease activation, providing insights into the pathway's specificity and regulation (Garred et al., 2016).

2.3. Alternative Pathway: Continuous Surveillance System

The alternative pathway functions as a constant, low-level surveillance system through spontaneous hydrolysis of the thioester bond in C3 to form C3(H2O) in a process termed "tick-over" (Hourcade et al., 2019). This conformationally altered C3 mimics C3b and binds factor B, which is cleaved by factor D to form the initial fluid-phase C3 convertase (C3(H2O)Bb). This convertase amplifies complement activation by generating additional C3b molecules that deposit on cellular surfaces. On non-protected surfaces, deposited C3b binds factor B, leading to formation of the membrane-bound alternative pathway C3 convertase (C3bBb), which is stabilized by properdin. The alternative pathway provides critical amplification for all activation pathways and serves as the primary defense against pyogenic bacteria, with recent evidence suggesting its involvement in sterile inflammation and tissue homeostasis (Hourcade et al., 2019).

3. Effector Mechanisms and Terminal Pathway

All three activation pathways converge at the cleavage of C3, initiating powerful effector functions and the terminal pathway that culminates in formation of the membrane attack complex.

3.1. Opsonization and Phagocytosis

C3 cleavage generates C3b and its degradation products iC3b and C3dg, which serve as potent opsonins that enhance phagocytosis by neutrophils and macrophages through binding to complement receptors CR1, CR3, and CR4 (Bajic et al., 2015). This process represents a crucial mechanism for clearance of pathogens and immune complexes, effectively linking innate and adaptive immunity. Opsonization also facilitates antigen presentation and modulates B-cell responses, highlighting complement's role in immune regulation beyond direct pathogen elimination.

3.2. Anaphylatoxin Signaling

Proteolytic cleavage of C3 and C5 generates the anaphylatoxins C3a and C5a, which exert potent pro-inflammatory effects through specific G-protein-coupled receptors (C3aR and C5aR1/C5aR2) (Klos et al., 2013). These peptides induce mast cell degranulation, increase vascular permeability, and recruit inflammatory cells through chemotaxis. Beyond their classical inflammatory roles, anaphylatoxins modulate adaptive immune responses by influencing T-cell differentiation and dendritic cell maturation, demonstrating the pleiotropic nature of complement signaling.

3.3. Membrane Attack Complex (MAC) Formation

The terminal pathway culminates in sequential assembly of the MAC (C5b-9), which creates transmembrane pores in target cell membranes (Muller-Eberhard, 1986). Initiated by C5 cleavage, the complex forms through sequential addition of C6, C7, C8, and multiple C9 molecules. While complete MAC insertion leads to osmotic lysis of pathogens, sublytic MAC deposition on host cells activates signaling pathways involved in cell proliferation, inflammation, and tissue repair, revealing complex context-dependent functions beyond direct cytolysis.

4. Complement Regulatory Networks

To prevent inappropriate activation and host tissue damage, the complement system is tightly regulated by an elaborate network of fluid-phase and membrane-bound inhibitors that operate at multiple levels of the cascade.

4.1. Fluid-Phase Regulation

Factor I, with cofactors including factor H and C4b-binding protein (C4BP), inactivates C3b and C4b through proteolytic cleavage (Rodríguez de Córdoba et al., 2019). Factor H plays a particularly critical role in regulating the alternative pathway by distinguishing host cells (rich in sialic acid and glycosaminoglycans) from pathogen surfaces. Other important fluid-phase regulators include C1 inhibitor (C1-INH), which controls classical and lectin pathway initiation by inactivating C1r and C1s; and clusterin and vitronectin, which inhibit MAC formation by preventing C9 polymerization.

4.2. Membrane-Bound Regulators

Host cells express multiple membrane proteins that provide protection against complement-mediated damage, including decay-accelerating factor (DAF/CD55), which dissociates C3 convertases; membrane cofactor protein (MCP/CD46), which serves as a cofactor for factor I-mediated cleavage of C3b and C4b; and CD59, which prevents MAC assembly by inhibiting C9 incorporation (Liszewski et al., 2017). Complement receptor 1 (CR1/CD35) exhibits both regulatory functions and roles in immune complex clearance, while newer research has identified intracellular complement activities that expand the traditional view of complement regulation.

5. Pathological Consequences of Complement Dysregulation

Dysregulation of complement activation underlies numerous human diseases, broadly categorized into deficiencies leading to increased infection susceptibility and excessive activation causing inflammatory tissue damage.

5.1. Autoimmune and Renal Diseases

In systemic lupus erythematosus (SLE), complement activation contributes to tissue injury, particularly in lupus nephritis, while inherited deficiencies of early classical pathway components (C1q, C4, C2) paradoxically increase SLE risk due to impaired clearance of apoptotic cells and immune complexes (Leffler et al., 2014). In autoimmune kidney diseases, complement activation plays a central role in the pathogenesis of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis and C3 glomerulopathies, where genetic mutations in complement regulators lead to uncontrolled alternative pathway activation.

5.2. Hematological Disorders

Atypical hemolytic uremic syndrome (aHUS) is strongly associated with mutations in alternative pathway regulators (factor H, factor I, membrane cofactor protein) leading to uncontrolled complement activation on endothelial cells (Noris and Remuzzi, 2013). Similarly, paroxysmal nocturnal hemoglobinuria (PNH) results from acquired deficiency of GPI-anchored complement regulators (CD55 and CD59) on blood cells, rendering them susceptible to complement-mediated intravascular hemolysis. These diseases have served as paradigms for understanding complement pathophysiology and developing targeted therapies.

5.3. Ocular and Neurological Disorders

Age-related macular degeneration (AMD), a leading cause of blindness, is characterized by complement deposition in drusen, with strong genetic associations linking alternative pathway regulators (factor H, factor B, C3) to disease risk (Anderson et al., 2019). Complement activation has also been implicated in Alzheimer's disease, where it may contribute to neuroinflammation and synapse elimination, and in neuromyelitis optica, where aquaporin-4 antibodies activate complement causing astrocyte damage and demyelination.

6. Therapeutic Targeting and Clinical Applications

The growing understanding of complement pathophysiology has spurred development of targeted therapeutics, with several agents now approved and many more in clinical development.

6.1. Approved Complement Therapeutics

Eculizumab, a monoclonal antibody against C5, has revolutionized treatment of PNH and aHUS by preventing MAC formation (Hillmen et al., 2021). Ravulizumab, a longer-acting anti-C5 antibody, reduces dosing frequency while maintaining efficacy. C1 esterase inhibitor concentrates are effective in hereditary angioedema, while pegcetacoplan, a C3 inhibitor, offers a novel approach for PNH treatment by targeting upstream complement activation (Risitano et al., 2022).

6.2. Emerging Therapeutic Strategies

Novel agents in advanced development include factor B inhibitors (e.g., iptacopan), properdin antagonists, and targeted compstatin analogs that inhibit C3 activation (Risitano et al., 2022). Gene therapy approaches are being explored for complement-mediated diseases, particularly those affecting the eye, while bispecific antibodies and targeted delivery systems offer promise for tissue-specific complement modulation with reduced systemic immunosuppression.

7. Future Perspectives and Research Directions

The complement field continues to evolve with several promising research directions that will shape future understanding and therapeutic applications:

7.1. Systems Biology and Omics Approaches

Integration of complement biology with systems-level analyses using proteomics, transcriptomics, and genomics will provide comprehensive insights into complement's role in health and disease (Reis et al., 2019). Single-cell technologies are revealing unexpected cell-type-specific complement production and regulation, expanding our understanding of local complement activities.

7.2. Complement in Tissue Homeostasis and Development

Emerging evidence indicates roles for complement in tissue regeneration, synaptic pruning, and metabolic regulation, suggesting functions beyond traditional immune defense (Reis et al., 2019). These discoveries open new avenues for therapeutic intervention in degenerative and developmental disorders.

7.3. Biomarker Development and Personalized Medicine

Identification of complement activation products as diagnostic and prognostic indicators will enable more precise disease monitoring and treatment selection. Genetic profiling of complement regulators may guide personalized therapeutic approaches for complement-mediated diseases.

7.4. Novel Therapeutic Modalities

Advances in antibody engineering, RNA therapeutics, and gene editing technologies offer new opportunities for complement modulation. Tissue-targeted delivery systems and small molecule inhibitors may provide improved specificity and reduced side effects compared to current biologic approaches.

In conclusion, the complement system represents a sophisticated immune surveillance network whose balanced regulation is essential for health. While complement activation provides crucial defense against pathogens, its dysregulation contributes to numerous inflammatory and degenerative conditions. The continued development of complement-targeted therapies holds promise for treating these diverse diseases, with future advances likely to emerge from deeper understanding of complement's complex roles in human physiology and pathology. The integration of basic research findings with clinical applications will continue to drive innovations in complement-based diagnostics and therapeutics.

References

Anderson, D. H., Radeke, M. J., Gallo, N. B., Chapin, E. A., Johnson, P. T., Curletti, C. R., Hancox, L. S., Hu, J., Ebright, J. N., Malek, G., Hauser, M. A., Rickman, C. B., Bok, D., Hageman, G. S., and Johnson, L. V. (2019). The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Progress in Retinal and Eye Research, 69, 1-29.

Bajic, G., Degn, S. E., Thiel, S., and Andersen, G. R. (2015). Complement activation, regulation, and molecular basis for complement-related diseases. The EMBO Journal, 34(22), 2735-2757.

Bohlson, S. S., Garred, P., Kemper, C., and Tenner, A. J. (2019). Complement nomenclature—deconvoluted. Frontiers in Immunology, 10, 1308.

Garred, P., Genster, N., Pilely, K., Bayarri-Olmos, R., Rosbjerg, A., Ma, Y. J., and Skjoedt, M. O. (2016). A journey through the lectin pathway of complement—MBL and beyond. Immunological Reviews, 274(1), 74-97.

Hillmen, P., Szer, J., Weitz, I., Röth, A., Höchsmann, B., Panse, J., and Usuki, K. (2021). Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. New England Journal of Medicine, 384(11), 1028-1037.

Hourcade, D. E., Mitchell, L. M., and Medof, M. E. (2019). The role of properdin in the assembly of the alternative pathway C3 convertases of complement. Journal of Biological Chemistry, 294(40), 14524-14535.

Klos, A., Wende, E., Wareham, K. J., and Monk, P. N. (2013). International Union of Basic and Clinical Pharmacology. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacological Reviews, 65(1), 500-543.

Leffler, J., Bengtsson, A. A., and Blom, A. M. (2014). The complement system in systemic lupus erythematosus: an update. Annals of the Rheumatic Diseases, 73(9), 1601-1606.

Liszewski, M. K., Elvington, M., Kulkarni, H. S., and Atkinson, J. P. (2017). Complement's hidden arsenal: new insights and novel functions inside the cell. Molecular Immunology, 84, 2-9.

Merle, N. S., Church, S. E., Fremeaux-Bacchi, V., and Roumenina, L. T. (2015). Complement system part I—molecular mechanisms of activation and regulation. Frontiers in Immunology, 6, 262.

Morgan, B. P. (2018). Complement in the pathogenesis of Alzheimer's disease. Seminars in Immunopathology, 40(1), 113-124.

Muller-Eberhard, H. J. (1986). The membrane attack complex of complement. Annual Review of Immunology, 4(1), 503-528.

Noris, M., and Remuzzi, G. (2013). Overview of complement activation and regulation. Seminars in Nephrology, 33(6), 479-492.

Reis, E. S., Mastellos, D. C., Hajishengallis, G., and Lambris, J. D. (2019). New insights into the immune functions of complement. Nature Reviews Immunology, 19(8), 503-516.

Ricklin, D., Reis, E. S., and Lambris, J. D. (2016). Complement in disease: a defence system turning offensive. Nature Reviews Nephrology, 12(7), 383-401.

Risitano, A. M., Marotta, S., Ricci, P., Marano, L., and Frieri, C. (2022). Complement as a target in COVID-19? Nature Reviews Immunology, 22(2), 125-126.

Rodríguez de Córdoba, S., Hidalgo, M. S., and Pinto, S. (2019). The complement system in the pathophysiology of pregnancy and in systemic autoimmune rheumatic diseases during pregnancy. Frontiers in Immunology, 10, 2954.